- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
Johnson & Johnson pauses COVID-19 vaccine trial after patient's 'unexplained illness'
The company says it is investigating before determining next steps in the COVID-19 vaccine trial.
Johnson & Johnson announced Monday that the company is pausing its phase 3 COVID-19 vaccine trial after a clinical trial participant contracted an "unexplained illness," the company said in a statement.
The pause in the closely watched trial, dubbed ENSEMBLE, was first reported by STAT News.
"We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant," the company statement read.
The company said that such outcomes are common in clinical trials, and stressed the difference between a study pause — which could be a short and only temporary occurence — and a regulatory hold, which is a formal action by the FDA that can mean much longer delays.
The company said it is undertaking a "careful review of all of the medical information before deciding whether to restart the study."
The ENSEMBLE trial began in late September, and is one of nearly a dozen phase 3 trials as pharmaceutical companies race to develop a COVID-19 vaccine, according to a tracking database published by the New York Times. ENSEMBLE involves more than 60,000 volunteer patients across three continents.
It is not the only COVID-19 vaccine trial that has had to halt investigations. In early sepetmber, the vaccine candidate from AstraZeneca and Oxford University paused for a "side effect" experienced by a patient. That trial resumed about a week later in the United Kingdom, but remains on hold in the United States.
